Bio-Rad Completes Purchase of Diamed

By HospiMedica staff writers
Posted on 07 Nov 2007

Bio-Rad Laboratories, Inc. (Hercules, CA, USA), a manufacturer and distributor of clinical diagnostics and life science research, announced that it has completed the purchase of DiaMed Holding AG (Cressier, Switzerland) for approximately US$411 million.

DiaMed develops, manufactures, and markets a complete line of reagents and instruments used in blood typing and screening. DiaMed has annual sales of approximately $200 million to hospitals, clinical laboratories, and blood banks in more than 100 countries.

"We are very pleased to have DiaMed join Bio-Rad,” said Norman Schwartz, Bio-Rad president and CEO. "DiaMed has an exceptional reputation for quality and customer care, and we believe the company and its portfolio of products will fit in well with Bio-Rad's current diagnostics business.”

Bio-Rad Laboratories, which is a company that supplies hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies worldwide, had revenues of nearly $1.3 billion in 2006.

Related Links:
Bio-Rad Laboratories
DiaMed